294 related articles for article (PubMed ID: 11889501)
1. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression.
Weinstock M; Poltyrev T; Bejar C; Youdim MB
Psychopharmacology (Berl); 2002 Mar; 160(3):318-24. PubMed ID: 11889501
[TBL] [Abstract][Full Text] [Related]
2. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Weinstock M; Bejar C; Wang RH; Poltyrev T; Gross A; Finberg JP; Youdim MB
J Neural Transm Suppl; 2000; (60):157-69. PubMed ID: 11205137
[TBL] [Abstract][Full Text] [Related]
3. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
4. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
Weinstock M; Gorodetsky E; Poltyrev T; Gross A; Sagi Y; Youdim M
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):555-61. PubMed ID: 12787840
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
Sagi Y; Weinstock M; Youdim MB
J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Youdim MB; Weinstock M
Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
[TBL] [Abstract][Full Text] [Related]
7. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor.
Maruyama W; Weinstock M; Youdim MB; Nagai M; Naoi M
Neurosci Lett; 2003 May; 341(3):233-6. PubMed ID: 12697291
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.
Weinstock M; Kirschbaum-Slager N; Lazarovici P; Bejar C; Youdim MB; Shoham S
Ann N Y Acad Sci; 2001 Jun; 939():148-61. PubMed ID: 11462767
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
10. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.
Yogev-Falach M; Amit T; Bar-Am O; Weinstock M; Youdim MB
FASEB J; 2002 Oct; 16(12):1674-6. PubMed ID: 12206996
[TBL] [Abstract][Full Text] [Related]
11. Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task.
Buccafusco JJ; Terry AV; Goren T; Blaugrun E
Neuroscience; 2003; 119(3):669-78. PubMed ID: 12809688
[TBL] [Abstract][Full Text] [Related]
12. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Int Rev Neurobiol; 2011; 100():191-215. PubMed ID: 21971009
[TBL] [Abstract][Full Text] [Related]
13. Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Youdim MB; Amit T; Bar-Am O; Weinstock M; Yogev-Falach M
Ann N Y Acad Sci; 2003 May; 993():378-86; discussion 387-93. PubMed ID: 12853332
[TBL] [Abstract][Full Text] [Related]
14. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
Yogev-Falach M; Bar-Am O; Amit T; Weinreb O; Youdim MB
FASEB J; 2006 Oct; 20(12):2177-9. PubMed ID: 16935943
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
16. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Curr Drug Targets; 2012 Apr; 13(4):483-94. PubMed ID: 22280345
[TBL] [Abstract][Full Text] [Related]
17. Effects of some anxiogenic agents on rat brain monoamine oxidase (MAO) A and B inhibitory (tribulin) activity.
Bhattacharya SK; Chakrabarti A; Sandler M; Glover V
Indian J Exp Biol; 1996 Dec; 34(12):1190-3. PubMed ID: 9246908
[TBL] [Abstract][Full Text] [Related]
18. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
Sagi Y; Driguès N; Youdim MB
Br J Pharmacol; 2005 Oct; 146(4):553-60. PubMed ID: 16086033
[TBL] [Abstract][Full Text] [Related]
19. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
20. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
